This was also demonstrated by Cho and colleagues [29] in HER2 + advanced gastric cancer patients treated with first-line fluoropyrimidine–platinum doublet plus trastuzumab, and by Lee and colleagues [50] in pancreatic ductal adenocarcinoma treated with conventional chemotherapy, where low dynamic NKA was associated with worse PFS and OS. The gene discussed is ERBB2; the disease is pancreatic ductal adenocarcinoma.